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Abstract
Background: Lung disease (LD) due to non-tuberculous mycobacteria is an important clinical concern.
Mycobacterium avium complex (MAC) is one of the most common causative agents but the diagnosis of MAC-LD
remains challenging. Detection of serum IgA antibody against MAC glycopeptidolipid (GPL) has recently been shown
to improve the diagnosis of MAC-LD, but has yet to be validated worldwide.
Methods: This prospective study was conducted in a tertiary referral center in northern Taiwan and enrolled patients
with MAC-LD, MAC contamination, other lung diseases, and control subjects. Serum immunoglobulin A (IgA)
antibody against MAC-GPL was detected in the participants and its specificity and sensitivity was assessed.
Results: There were 56 patients with MAC-LD, 11 with MAC contamination, 13 M. kansasii-LD, 26 LD due to rapidly-
growing mycobacteria (RGM), 48 pulmonary tuberculosis, and 42 household contacts of patients with TB. Patients
with MAC-LD were older and 32% of them had an underlying co-morbidity. By logistic regression, serum MAC-GPL
IgA level was an independent predictor of MAC-LD among the study subjects and those with culture-positive
specimens for MAC. By the receiver operating characteristic curve, serum MAC-GPL IgA had a good power to
discriminate MAC-LD from MAC contamination. Under the optimal cut-off value of 0.73 U/mL, its sensitivity and
specificity were 60% and 91%, respectively. Among MAC-LD patients, presence of co-morbidity was associated with
MAC-GPL <0.73 U/ml in logistic regression analysis.
Conclusions: Measurement of serum anti-MAC-GPL IgA level is useful for the diagnosis of MAC-LD. However, its
implement in clinical practice for immuno-compromised hosts needs careful consideration.
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Introduction
Lung disease (LD) due to non-tuberculous mycobacteria
(NTM) is an important clinical concern because the incidence
and prevalence of NTM diseases have increased over the last
ten years [1,2]. According to a study in Taiwan, a tuberculosis
(TB) endemic area, NTM-LD increased from 1.26 to 7.94 per
100,000 in-patients per year from 2000 to 2008 [2]. Among the
NTM diseases in Asia, Mycobacterium avium complex (MAC)
is the most common cause of NTM-LD [2,3].
The diagnosis of MAC-LD is complicated because unlike
Mycobacterium tuberculosis, MAC contamination of clinical
specimens can come from environmental sources such as
water, dust, and soil. It may colonize the respiratory tract
without any accompanying invasive disease [4]. Thus, isolation
of MAC from sputum is insufficient to document pulmonary
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infection. Previous studies have shown that the presence of
MAC has a clinical relevance of around 35-42% [5,6].
According to guidelines of the American Thoracic Society
(ATS) [1], the diagnosis of pulmonary disease due to
Mycobacterium avium complex (MAC) is based on clinical,
radiographic, and mycobacterial criteria. Thus, the entire
process is complicated and time consuming, requiring clinical
findings and repeated MAC isolation/culture from sputum.
Moreover, it is very difficult to discriminate between MAC
contamination and MAC-LD [7,8], or between MAC-LD and
other mycobacterial infections without culture results. Clinical
features such as symptomatic or radiographic findings are very
similar in mycobacterial diseases. From the standpoint of
infection control, it is particularly important to distinguish
between MAC-LD and pulmonary tuberculosis (TB). Therefore,
tests that can rapidly and accurately differentiate between
MAC-LD and MAC contamination are needed.
Among sero-diagnostic methods, detection of serum
immunoglobulin A (IgA) antibody against MAC
glycopeptidolipid (GPL), an important antigenic component of
MAC bacterial wall, has been recently developed. It shows
good diagnostic performance in Japan (MAC-GPL IgA, Tauns
Laboratory Inc., Shizuoka, Japan) [9,10]. However, a study
conducted in the United States reveals that the test is specific
but less sensitive (70%) when the same cut-off value (0.7
U/mL) is used, despite sufficient sensitivity (80%) obtained at
0.3 U/mL as the cut-off value [11]. The studies in Japan have
included immunocompetent patients, but a small number of
immunocompromised patients such as lung cancer, and did not
examined patients with diseases due to rapidly growing
mycobacteria (RGM) possessing glycopeptidolipid antigen
such as M. abscessus, M. fortuitum, and M. chelonae [9,10].
Therefore, the sero-diagnostic test requires validation in
different ethnicities and geographic locations with variable
background prevalence of M. tuberculosis and NTM. This study
examined the clinical availability of the sero-diagnostic test for
MAC-GPL IgA, including sensitivity and specificity, in Taiwan.
Materials and Methods
Patient enrollment
This prospective study was conducted at National Taiwan
University Hospital in Taipei from January 2011 to January
2013. The hospital’s research ethics committee approved the
study and all participants provided written informed consent.
Patients aged >20 years and had respiratory sample(s) culture-
positive for NTM were identified. Among them, we enrolled
patients with MAC-LD, MAC contamination, rapidly growing
mycobacteria (RGM, including M. abscessus, M. fortuitum, and
M. chelonae)-LD or M. kansasii-LD diagnosed according to the
ATS diagnostic guideline [1]. Patients with culture-proven
pulmonary TB and their household contacts who had a result of
interferon-gamma release assay (IGRA) but no clinical
symptoms and radiographic findings suggestive for active
pulmonary disease in the last 6 months were also enrolled. In
this study, IGRA was performed by using T-SPOT.TB (Oxford
Immunotech Ltd, Oxford, UK) [12]
Mycobacterial culture and species identification was
performed as previously described [13]. Patients with human
immunodeficiency virus (HIV) infection and bleeding tendency
that increased the risk of blood sampling were excluded.
MAC-GPL IgA antibody measurement
All samples were stored in -20°C and examined in random
order by a technician blinded to the patients’ clinical diagnoses.
Serum MAC-GPL IgA was measured by an enzyme
immunoassay kit (Tauns Laboratory Inc., Shizuoka, Japan)
according to the manufacturer’s instructions. Data was
expressed as U/mL in reference to standard curve using
positive controls.
Data collection
Clinical data, including age, sex, co-morbidities, history of
pulmonary TB, and laboratory data at enrollment was recorded
in a standardized case report form. Disease duration was
defined as the period between the date of the first confirmed
positive culture and the date of patient enrollment with NTM-LD
and pulmonary TB. Typical histology of NTM infection included
granulomatous inflammation and/or presence of acid fast bacilli
[1]. Chest imaging was interpreted as noted in a previous study
[3]. Radiographic patterns of the main pulmonary lesion were
categorized as consolidative, fibro-cavitary, or nodular-
bronchiectatic.
Statistical analysis
Inter-group differences were analyzed by the student t test or
Mann-Whitney U test for numerical variables, and chi-square
test or Fisher’s exact test for categorical variables, as
appropriate. Multivariate logistic regression analysis was
applied to identify factors associated with MAC-LD. In the
stepwise variable selection procedure, all potential predictors
were included. Statistical significance was set at a two-sided
p<0.05.
The discriminative power of each significant predictor
between MAC-LD and other groups or MAC contamination was
compared using the receiver operating characteristic (ROC)
curve and the area under the curve (AUC). The optimal cut-off
value, defined as the one with the least (1 - sensitivity)2 + (1 -
specificity), was used to calculate sensitivity and specificity
[14]. All analyses were performed using the SPSS (Version
15.0, Chicago, IL).
Results
The study enrolled 56 patients with MAC-LD, 11 with MAC
contamination, 14 with M. kansasii-LD, 26 with RGM-LD (14 M.
abscessus, 7 M. fortuitum, and 5 M. chelonae), 48 with
pulmonary TB, and 42 TB household contacts. Among the 42
household contacts, 22 (19 without underlying disease) were
IGRA-positive and the remaining 20 (18 without underlying
disease) were IGRA-negative.
Among the MAC-LD patients, the mean age was 67.8 years,
50% were male, and 32% had co-morbidity (Table 1). Seven
MAC-LD patients had malignancies, including two with lung
cancer and one each with buccal cancer, leukemia, hepatoma,
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cholangiocarcinoma, and bladder cancer. Among the 56 MAC-
LD patients, respiratory specimens were smear-positive for
acid-fast bacilli in 33 (59%), including 10 with high-grade
(3+~4+) positivity. Fifty one MAC-LD patients had ≥2 sputum
samples culture-positive for MAC (average, 5.2 sets [SD: 2.8]).
In five MAC-LD patients with only one positive sputum culture,
four had typical lung histology and the remaining one had one
bronchial washing culture positive for MAC. Based on the
radiographic pattern, six (11%), nine (16%), and 41 (73%) were
classified as consolidative, fibro-cavitary, and nodular-
bronchiectatic lung diseases, respectively.
Among patients with MAC contamination, the mean age was
60.9 years and 64% were male. All had ≥3 sets of sputum for
acid-fast smear and mycobacterial culture. Except for one who
had three culture-positive sputum samples but normal chest
radiography, all of the patients had only one culture-positive
sputum sample. Two of the 11 persons with MAC
contamination had low-grade positive acid-fast smear.
Patients with MAC-LD were older than those with M.
kansasii-LD, pulmonary TB, and TB contacts (Table 1).
Disease duration was 13.2 months in average in the MAC-LD
group and this was longer than those in the M. Kansasii-LD,
RGM-LD, and pulmonary TB groups. In the MAC-LD group, 24
patients (42%) had disease duration less than 3 months,
including 10 who were started on anti-MAC treatment upon
enrollment. Prior TB history was more common in the NTM-LD
group than in the PTB and control groups. Laboratory data,
including blood hemoglobin and leukocyte count, were similar
among all groups.
Regarding MAC-GPL IgA, MAC-LD patients had significantly
higher serum levels than all of the other groups (Figure 1).
Multivariate logistic regression revealed that age (odds ratio
[OR]: 1.032; 95% CI: 1.005-1.060), presence of autoimmune
disease (OR: 4.884; 95% CI: 1.038-22.971), and serum MAC-
GPL IgA antibody level (OR: 1.325; 95% CI: 1.144-1.536) were
independent predictors of MAC-LD (Table 2). As regards
patients with respiratory specimen(s) culture-positive for MAC,
only MAC-GPL IgA level (OR: 2.856; 95% CI: 1.045-7.805)
remained a significant factor for differentiating MAC-LD from
MAC contamination.
The ROC curve analysis revealed that serum MAC-GPL IgA
had high discriminative power for MAC-LD from all other
groups (AUC 0.805, p<0.001) (Figure 2A), all other groups
except RGM-LD (AUC 0.821, p<0.001) (Figure 2B), or MAC
contamination (AUC 0.782; p=0.003) (Figure 2C). For
discriminating MAC-LD from all other groups, the optimal cut-
off value of serum MAC-GPL IgA was 0.26 U/ml (sensitivity
79%; specificity 76%). If the cut-off value was increased to 0.7
U/mL by the manufacturer's instruction, sensitivity and
specificity became 61% and 87%, respectively.
For discriminating MAC-LD from all other groups except
RGM-LD, the optimal cut-off value of MAC-GPL IgA was 0.26
U/ml (sensitivity 79%; specificity 80%). The optimal cut-off
value of MAC-GPL IgA to discriminate MAC-LD from MAC
contamination was 0.73 U/mL (sensitivity 60%; specificity
91%). If the cut-off value was lowered from 0.73 to 0.30 U/mL,
sensitivity increased to 75% but specificity decreased to 64%.
Using the cut-off value of 0.73 U/ml for discriminating MAC-LD
from all other groups, sensitivity was 61% and specificity 88%.
The proportion of sero-positive cases using 0.73 U/ml as the
cut-off value in each group was shown in Table 3. Seven (27%)
RGM-LD patients had positive MAC-GPL IgA test. The false-
positive rate in RGM-LD patients was significantly higher than
that in M. kansasii-LD patients (p=0.025) and TB household
contacts (p=0.033), and borderline higher than that in
pulmonary TB (p=0.066) patients. None of the IGRA-positive
TB household contacts had a positive result of the MAC-GPL
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Abbreviations: GPL, glycopeptidolipid; LD, lung disease; MAC, Mycobacterium
avium complex; NTM, non-tuberculous mycobacteria; PTB, pulmonary
tuberculosis; RGM, rapidly-growing mycobacteria
Data are no. (%) or mean [standard deviation]
*. p<0.05 between the indicated group and the MAC-LD group
**. RGM includes 14 M. abscessus, 7 M. fortuitum, and 5 M. chelonae
***. Malignancy includes 5 lung cancer, 4 head and neck cancer, 3 leukemia, 3
hepatoma, 2 breast cancer, 2 bladder cancer, 2 biliary tract cancer, and 1 thyroid
cancer
Autoimmune diseases includes 3 rheumatoid arthritis, and each one of systemic
lupus erythematosus, ankylosing spondilytis, Sjögren syndrome, Graves' disease,
and autoimmune related nephrotic syndrome
doi: 10.1371/journal.pone.0080473.t001
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Figure 1.  Serum immunoglobulin A antibody levels of Mycobacterium avium complex (MAC) glycopeptidolipid (GPL) in
different lung disease statuses.  IgA, immunoglobulin A; LD, lung disease; PTB, pulmonary tuberculosis; RGM, rapid-growing
mycobacteria.
doi: 10.1371/journal.pone.0080473.g001
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IgA, whereas two (11%) of the 18 IGRA-negative contacts
without underlying disease did.
In MAC-LD, patients with co-morbidity had lower MAC-GPL
antibody levels than those without (1.50 vs. 5.54 IU/ml,
p=0.009) and patients with malignancy had lower serum GPL
IgA levels than those without (0.40 vs. 4.70 IU/ml, p=0.018).
Within the MAC-LD group, patients with high smear grade had
higher serum MAC-GPL IgA levels than those with low smear
grade and negative smear (7.89 vs. 3.41 IU/mL, p=0.039). The
MAC-GPL IgA serum level was borderline higher in 46 MAC-
LD patients with ≥2 positive sputum cultures for MAC within six
months before blood sampling, compared to the other 10 MAC-
LD patients (4.76 vs. 2.01 U/mL, p=0.072). The ROC curve
predicting those with ≥2 sputum cultures positive for MAC
Table 2. Factors associated with Mycobacterium avium
complex-lung disease (MAC-LD), by multivariate logistic
regression.
Characteristics Multivariate
 p value OR (95% C.I.)
Age, per year increment 0.020 1.032 (1.005 ~ 1.060)
Sex, male 0.204  
Presence of underlying co-morbidity 0.341  
Malignancy 0.921  
Diabetes mellitus 0.270  
Liver cirrhosis 0.339  
Hemodialysis (chronic renal failure) 0.999  
Autoimmune disease 0.045 4.884 (1.038 ~ 22.971)
Blood leukocyte count, per L 0.236  
Hemoglobin, per g/dL 0.335  
MAC GPL antibody, per U/mL increment <0.001 1.325 (1.144 ~ 1.536)
Abbreviation: GPL, glycopeptidolipid
doi: 10.1371/journal.pone.0080473.t002
within six months from all participants with any sputum positive
for MAC revealed that serum MAC-GPL IgA had good
discriminative power (AUC 0.728, p=0.005) with the optimal
cut-off value of 0.73 U/mL (sensitivity 63%; specificity 78%).
The median MAC-GPL IgA serum level was similar between
those with and without prior TB history (1.32 vs. 1.47 U/ml, p =
0.982 by Mann-Whitney U test). The number of positive culture,
disease duration before blood sampling, started NTM
treatment, and radiographic pattern were not significantly
correlated with MAC-GPL IgA level. Among the 56 MAC-LD
patients, the average MAC-GPL IgA was similar in the 10 with
bronchoscopic specimen(s) positive for MAC and the other 46
without (4.11 vs. 4.99 U/mL, p=0.694).
In multivariate analysis for MAC-GPL IgA ≥0.73 U/ml in
MAC-LD, the presence of co-morbidity was the only
independent factor (OR: 0.218; 95% CI: 0.063-0.754) (p=0.016)
whereas positive culture for MAC ≥3 sets was a borderline
predictor (OR: 3.530; 95% CI: 0.866-14.395) (p=0.079).
Table 3. Number and proportion of sero-positive subjects in
each group based on the cut-off value of 0.73 U/ml for
Mycobacterium avium complex glycopeptidolipid antibody.
Clinical diagnosis Sero-positive, n (%)
MAC-LD (n=57) 34 (60%)
MAC contamination (n=11) 1 (9%)
M. kansasii-LD (n=13) 0
RGM-LD (n=26) 7 (27%)
Pulmonary TB (n=48) 5 (10%)
TB household contacts (n=42) 2 (5%)
Abbreviations: LD, lung disease; MAC, Mycobacterium avium complex; RGM,
rapid-growing mycobacteria; TB, tuberculosis
doi: 10.1371/journal.pone.0080473.t003
Figure 2.  The receiver operating characteristic (ROC) curves were plotted for predicting patients with Mycobacterium
avium complex (MAC)-lung disease in different population.  (A) all participants, (B) all except RGM-LD patients, and (C) those
with positive sputum culture for MAC. The numbers in parenthesis represent the corresponding sensitivity and specificity using the
specific cut-off value. AUC, area under curve; Sen, sensitivity; Spe, specificity.
doi: 10.1371/journal.pone.0080473.g002
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Discussion
In the present study, serum MAC-GPL IgA level is higher in
MAC-LD than MAC contamination and other mycobacterial
lung diseases. Using a cut-off value of 0.73 U/ml leads to an
intermediate sensitivity but excellent specificity for identifying
patients with MAC-LD. In MAC-LD, immuno-competence is
independently associated with higher serum MAC-GPL IgA
level.
Inflammatory markers like C-reactive protein, procalcitonin,
and interferon-gamma are poorly associated with NTM-LD.
Soluble triggering receptors expressed on myeloid cell-1 have
better correlation with NTM-LD though these are not
pathognomonic [7]. In contrast, MAC-GPL antibody is more
specific to MAC-LD and has been developed since the last
decade [9,10]. Such GPL belong to a class of glycolipids
produced by several NTM [15,16] and is an important element
in NTM cell wall. GPL is located in the outmost layer, and is
thus very antigenic [16]. A previous study conducted in a
Japanese population reported 100% specificity and 84%
sensitivity in differentiating MAC-LD from other lung disease
using a cut-off value of 0.7 U/ml for MAC-GPL IgA serum level
[10]. Such finding suggests that GPL of MAC is antigenic and
its antibody maybe a good diagnostic marker.
However, in a study conducted in the United States, the
sensitivity of MAC-GPL IgA for diagnosing MAC-LD from
contamination is only 51.7% and 70.1% using cut-off values of
0.7 and 0.3 U/ml, respectively [11]. Similarly, the present study
shows that MAC-GPL IgA has an intermediate sensitivity but
an excellent specificity for discriminating MAC-LD using a cut-
off value of 0.73 U/ml. It is not sensitive enough to be
diagnostic for MAC-LD in clinically suspected cases because of
the high false-negative rate.
The sub-optimal sensitivity of the MAC-GPL IgA test may be
explained by two reasons. First, previous studies mainly
included immunocompetent patients but 32% of the MAC-LD
patients in this study had some degree of immuno-
compromise, which was associated with lower GPL antibody.
The finding is similar to the study conducted in the US wherein
21% of the enrolled subjects were given immuno-suppressants.
In the MAC-LD patients here, immuno-compromised disease
such as malignancy was a major factor associated with low
MAC-GPL IgA serum level. The average MAC-GPL IgA in the
present study was around 4.3 U/ml, far less than the 10.7 U/ml
reported in the study in Japan. Because immuno-compromised
hosts have a higher probability of MAC-LD, further large-scale
prospective studies are required to evaluate diagnostic
performance in a population with different co-morbidity.
Second, the interval of sputum positivity may matter. The MAC-
LD patients without ≥2 positive sputum culture within the last
six months had lower MAC-GPL IgA level, suggesting that
proper timing after sputum positivity might be needed to apply
this sero-diagnostic test.
The discriminative power of MAC-GPL IgA test between
MAC-LD and RGM-LD is poor. The seropositivity rate is around
27% in diseases due to RGM, probably because GPL is also a
cell wall component in RGM [17]. Since culture turn-around-
time for RGM is usually less than one week [1], the diagnosis
of RGM-LD can possibly be immediately excluded in suspected
cases of MAC-LD. The specificity of MAC-GPL IgA test,
therefore, increases if patients with RGM-LD are excluded. For
the other groups, the false-positive rate is ≤10%, which is
comparable to those of previous reports [9,11]. This may be
explained by the immune response due to prior or
asymptomatic MAC infection [18]. Given the possible existence
of false-positive results, MAC-GPL IgA is not a suitable
diagnostic test for MAC-LD before the initial mycobacterial data
becomes available.
For a case of MAC contamination that is sero-positive for
MAC-GPL IgA antibody, MAC-LD may be underestimated
because of the low sensitivity of the ATS diagnostic criteria,
especially when the patient is unable to produce/expectorate
adequate sputum. However, anti-MAC chemotherapy is not
recommended until the diagnosis of MAC-LD has been
confirmed due to the possibility of adverse events [1,19]. The
serologic test for MAC-GPL IgA may thus be useful for patients
who have a respiratory sample culture-positive for MAC but in
whom invasive diagnostic procedures may be risky.
The present study has some limitations. First, the case
number studied is small, precluding a firm conclusion on the
clinical usefulness of the MAC-GPL IgA test. The diagnostic
strategy for each sub-group with different underlying diseases
should also be proven by a large-scale study in the future.
Second, since persons with MAC contamination are usually
asymptomatic, enrolling them into the study is much more
difficult than enrolling MAC-LD patients. Therefore, the number
of cases of MAC contamination is particularly small. Third,
although TB household contacts were free of active lung
disease, they may have been exposed to MAC. Lastly,
because the study was conducted in a tertiary referral center,
the prevalence of co-morbidity was high, thus limiting the
external generalization of the study.
In conclusion, serum level of MAC-GPL IgA antibody is
higher in MAC-LD than MAC contamination and other lung
diseases. Using a cut-off value of 0.73 U/mL leads to an
intermediate sensitivity (60%) but good specificity (91%) for
differentiating MAC-LD from MAC contamination. This might be
helpful in suggesting pulmonary infection by MAC when a
respiratory specimen was culture-positive for MAC but further
invasive diagnostic procedure like bronchoscopy is risky.
Careful consideration is needed while using MAC-GPL IgA
antibody in immuno-compromised hosts.
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